Integrative Proteomic and Transcriptomic Analysis Provides Evidence for TrkB (NTRK2) as a Therapeutic Target in Combination With Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer
Oncotarget - United States
doi 10.18632/oncotarget.24361
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 31, 2018
Authors
Publisher
Impact Journals, LLC